Pharmacokinetically-guided dosing of pemetrexed in a patient with renal impairment and a patient requiring hemodialysis

Pemetrexed is a pharmacotherapeutic cornerstone in the treatment of non-small cell lung cancer (NSCLC) and mesothelioma. It is mainly excreted renally, but dosing is based on body surface area (BSA) and does not take renal function into account. Impaired renal function (estimated creatinine clearance

Source: Lung Cancer - February 1, 2019 Category: Cancer & Oncology Authors: N. de Rouw, S. Croes, R. Posthuma, D.E. Agterhuis, J.J.A.O. Schoenmaekers, H.J Derijks, D.M. Burger, A.M. Dingemans, R. ter Heine Source Type: research